Drugs / Twinrix™ Junior
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00197184 | Nov 2003 → Mar 2004 | hepatitis A virus infection, hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04294433 | Jun 2018 → Dec 2023 | hepatitis B virus infection | Laval University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00197119 Comparator | May → Jun 2004 | hepatitis A virus infection, hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Twinrix Junior | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00197184 ↗ |
| Modality | Vaccine | “2 Formulations of Combined Hepatitis A/B Vaccine Compared” NCT00197119 ↗ |
| Route | Intramuscular | “Intramuscular administration in the deltoid region (3 doses).” NCT00197119 ↗ |